TSHA - Company ID 0001806310
The table below shows Taysha Gene Therapies, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $1.99M | $2.30M | $1.79M | $1.11M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $33.81M | $25.75M | $20.14M | $15.56M | $14.95M | $15.07M |
Taysha Gene Therapies, Inc. reported annual revenue of $9.77M for fiscal year 2025. That is up 17.3% from $8.33M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $9.68M |
| $8.28M |
| $8.60M |
| $8.16M |
| $7.90M |
| $7.34M |
| Operating income | -$43.49M | -$34.02M | -$26.75M | -$21.42M | -$25.90M | -$21.30M |
| Income tax | $0.00 | - | - | $0.00 | - | - |
| Net income | -$42.41M | -$32.73M | -$26.88M | -$21.53M | -$25.52M | -$20.93M |
| EPS (diluted) | -$0.12 | -$0.09 | -$0.09 | -$0.08 | -$0.10 | -$0.09 |